Compare Novavax Inc (NVAX) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Zillow Group Inc Class C — how do they compare? Novavax Inc trades at $12 (market cap $1.82B), while Zillow Group Inc Class C trades at $28.74 (market cap $6.59B). The key difference: Zillow Group Inc Class C is far larger — about 3.6× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Zillow Group Inc Class C nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Zillow Group Inc Class C for 39 Days on average.
| NVAX | Z | |
|---|---|---|
Market Cap | $1.82B | $6.59B |
Volume | 6,198,505 | 9,134,294 |
Sector | Health | Media |
52-Week High | $12.56 | $78.04 |
52-Week Low | $6.22 | $27.13 |
Typical Hold Time | 59 Days | 39 Days |
Enterprise Value | $1.39B | $6.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
Zillow Group (Z) trades at $28.65, up 5.02% over 24 hours, with a bullish technical signal despite mixed moving averages. The company reported revenue of $2.58 billion in 2025, turning a net profit of $23 million after a loss in 2024, and shows improving margins. Recent news highlights AI integration in real estate and resolution of an FTC lawsuit, while the housing market faces affordability challenges.
The outlook is cautiously optimistic with a consensus price target of $60.33, implying significant upside, but risks include sensitivity to mortgage rates and competitive pressures. Earnings have beaten expectations in two of the last three quarters, supporting growth potential amid a volatile housing sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
